Asthma is a common condition characterised by inflammation, airway hyperresponsiveness and reversible airflow obstruction. Effective pharmacotherapy must therefore be aimed at attenuating these underlying hallmark features. Despite the use of regular low-to-moderate doses of inhaled corticosteroids, many patients remain symptomatic and require further 2nd line controller therapy. The addition of a concomitant long acting b 2 -agonist provides an effective means in which to alleviate symptoms and reduce exacerbation frequency. Moreover, both agents can be combined in a single inhaler, and provide patients with a more convenient and effective way in which to deliver treatment to the endobronchial tree. This evidenced-based review article discusses the effects of such combination inhalers upon a variety of outcome parameters and their effects upon asthmatics across a range of severities.
Summary Asthma is a common condition characterised by inflammation, airway hyperresponsiveness and reversible airflow obstruction. Effective pharmacotherapy must therefore be aimed at attenuating these underlying hallmark features. Despite the use of regular low-to-moderate doses of inhaled corticosteroids, many patients remain symptomatic and require further 2nd line controller therapy. The addition of a concomitant long acting b 2 -agonist provides an effective means in which to alleviate symptoms and reduce exacerbation frequency. Moreover, both agents can be combined in a single inhaler, and provide patients with a more convenient and effective way in which to deliver treatment to the endobronchial tree. This evidenced-based review article discusses the effects of such combination inhalers upon a variety of outcome parameters and their effects upon asthmatics across a range of severities. & 2004 Elsevier Ltd. All rights reserved. 
Introduction
Asthma is a common chronic heterogeneous condition which displays a complex and varied phenotypic picture. It can present in early childhood as well as adulthood, and varies markedly in severity, clinical course, subsequent disability and response to treatment. Pathologically it is characterised by inflammation, physiologically by airway hyperresponsiveness (AHR) and consequent airflow obstruction, and clinically by wheeze, chest tightness, breathlessness and cough. 1 Symptoms are the final manifestation of a complex interplay between an array of inflammatory cells and mediators, which cause airway smooth muscle to intermittently contract and relax.
Apart from the short-term consequences of troublesome symptoms, absence from work, hospital admissions and risks associated with an acute exacerbation, long-term deleterious consequences of asthma are well recognised. For example, individuals with asthma have a more rapid rate of decline in lung function than non-asthmatics 2 and previous studies have demonstrated that asthmatics with impaired lung function experience a higher mortality rate. 3, 4 Furthermore, if inflammation is left untreated, asthma can progress towards a less reversible entity in which airways become permanently narrowed along with thickening of bronchial lumen walls. 5 With the advent of fibreoptic bronchoscopy, endobronchial biopsy, bronchoalveolar lavage and sputum induction, it has become increasingly recognised that inflammation is a fundamental component in the pathophysiology of asthma. This knowledge has highlighted the need for timely and appropriate institution of anti-inflammatory therapy directed towards the endobronchial tree. Moreover, it has become apparent that in addition to anti-inflammatory therapy, reversal of co-existant bronchospasm with the use of a long acting b 2 -agonist (LABA) provides a commensurate improvement in asthma control. This evidencedbased review examines the current literature in terms of putative benefits of dealing concomitantly with corticosteroid responsive inflammation and reversible airflow obstruction with the combination of an inhaled corticosteroid plus LABA, respectively.
Inhaled corticosteroids
Inhaled corticosteroids are a vital component in the successful treatment of persistent asthma of all severities. 6 Once bound to cytoplasmic receptors concentrated in airway epithelial and endothelial cells, they increase and decrease the gene transcription of anti-inflammatory and pro-inflammatory mediators, respectively. Corticosteroids also exert a direct inhibitory effect upon a number of cells (eosinophils, T lymphocytes and epithelial cells) implicated in the asthmatic inflammatory process. As a consequence, they attenuate AHR over several weeks although the maximal effect may not be achieved until after several months of regular use. 7 Moreover, inhaled beclomethasone and fluticasone can prevent changes associated with long-term unchecked inflammation (airway remodelling). 8, 9 Dose-response studies using inhaled corticosteroids have generally been unable to demonstrate any significant difference between individual doses. For example, a meta-analysis by Holt et al. evaluated 8 studies (2324 asthmatics) where the effects of at least 2 doses of fluticasone were measured. 10 Most therapeutic gain (in terms of airway calibre, symptoms and effects upon exacerbations) was achieved at daily doses of fluticasone between 100 and 250 mg. However, the authors do acknowledge that the study was limited by paucity of data with higher fluticasone doses. It is also important to note that clinical outcome measures such as lung function, rescue medication use and symptoms fail to provide information regarding the intrinsic disease process itself and tend to be downstream markers relatively remote from AHR and underlying inflammation. 1 Indeed, using AHR as the primary outcome measure, a meta-analysis of 25 studies (963 patients) demonstrated that high doses (X1000 mg of beclomethasone or equivalent) of inhaled corticosteroid did confer greater improvements in terms of attenuating AHR than low doses (o1000 mg). 11 It is pertinent to be aware that this is at the expense of adverse local and systemic sequelae. However, patients with severe persistent asthma appear to be protected from high doses of inhaled corticosteroids due to decreased lung bioavailability as a consequence of reduced airway diameter. 12, 13 Adverse effects of inhaled corticosteroids tend to occur in a dose-dependant way. 14 Clinicians should therefore aim to have patients controlled on the lowest dose of inhaled corticosteroid which optimises airway benefit and minimises the risk of systemic adverse effects, thus improving the overall therapeutic ratio. Indeed, it is generally accepted that at daily doses greater than 800 mg of beclomethasone or equivalent in adults, the dose-response curve for desired effects becomes flat, while that for systemic adverse effects becomes steep. 15 Moreover, the relative flatness of the dose-response curve in terms of forced expiratory volume in 1 s (FEV 1 ) with inhaled corticosteroids suggests that concomitant treatment which maximally relaxes airway smooth muscle-especially in patients with impaired lung function-may be the way ahead in terms of optimal asthma control.
Long acting b 2 -agonists
LABAs were introduced in the early 1990s as an addition to the pharmacological armamentarium involved in the control of asthma. LABAs have two clinically important properties, namely a bronchodilator effect in the presence of low bronchomotor tone and a protective effect in the presence of increased bronchomotor tone (so-called functional antagonism). Functional antagonism can be evaluated by performing bronchial challenge tests and provides a way of assessing the protective effects of b 2 -agonists in the laboratory. Furthermore, bronchoprotection with LABAs can be considered to be a surrogate for airway stabilisation upon smooth muscle. 16 They have also been shown to suppress the release of inflammatory mediators from primed mast cells in the airway, 17, 18 reduce plasma exudation from airway endothelium 19, 20 and block bronchoconstricting sensory nerve activation in guinea pig bronchi. 21 Currently, salmeterol and eformoterol are the most commonly used LABAs in clinical practice. Both bind to airway smooth muscle b 2adrenoceptors and demonstrate a bronchodilating effect in excess of 12 hours after a single inhalation. 22 In contrast to short acting b 2agonists, LABAs are highly lipophilic which partly explains their prolonged duration of action. 23 The dose-response curve for salmeterol is relatively flat when 50 mg is exceeded, whereas eformoterol exhibits a dose-dependant relationship in terms of bronchoprotection to inhaled methacholine at doses up to 120 mg. 24 Salmeterol is a partial agonist and has a slower onset of action, while in contrast, eformoterol is a full agonist and demonstrates a quicker onset of bronchodilation. This pharmacological property can be exploited, allowing eformoterol to be used on an 'as required basis'. For example, in a 12 week, double blind, parallel group study, eformoterol 4.5 mg was shown to confer superior asthma control than terbutaline 0.5 mg when used for intermittent acute relief of symptoms. 25 It is important to be aware that LABAs do not exhibit in vivo anti-inflammatory activity. [26] [27] [28] For example, Lazarus et al. evaluated well controlled asthmatics using triamcinolone 800 mg/day and randomly switched them to receive salmeterol as monotherapy or continue with triamcinolone. 29 Patients assigned the former group experienced more exacerbations and demonstrated an increase in sputum and blood inflammatory markers. In another trial, Lemanske et al. randomised patients after a 6-week run-in not controlled on triamcinolone 800 mg/day, to receive either salmeterol or placebo. 30 During the next 4 months, inhaled corticosteroids were discontinued in the entire placebo group and in one-half of the salmeterol group. The mean overall treatment failures with either salmeterol or placebo were similar in both groups. In other words, add on salmeterol had no effects on disease control following discontinuation of triamcinolone. As a consequence, guidelines do not advocate the use of LABAs as monotherapy in asthmatics of any severity. 6 Polymorphisms of the b 2 -adrenoceptor have been identified, of which substitution of glycine for arginine at codon 16 (occurring in about 40% of the UK population), enhances the susceptibility to down regulation by b 2 -agonists. Due to prolonged receptor occupancy, the b 2 -adrenoceptor becomes internalised and degraded. As a result, an attenuated bronchoprotective response can be observed with different types of inhaled stimuli. 31, 32 Furthermore, in the clinical setting of an acute asthma attack, it may be relevant that a blunted response to inhaled salbutamol occurs with chronic treatment with LABAs. 33 However, there is little compelling evidence to suggest that tolerance develops to the bronchodilator effects of LABAs.
Corticosteroids and long acting b 2agonists used in combination
The use of an inhaled corticosteroid combined with a LABA in a single device is becoming an increasingly popular method of delivering drugs to the lung. Indeed, commonsense suggests that this is a reasonable pharmacological and financial option since inhaled corticosteroids are the most potent anti-inflammatory agents and LABAs the most potent bronchodilators used in asthma. Currently, salmeterol can be given with fluticasone in a single inhaler (Seretide), and eformoterol has been formulated with budesonide (Symbicort; Table 1 ). This has the potential advantage of improving patients compliance in view of fewer inhalations and inhaler devices required, while the fairly immediate bronchodilation especially with eformoterol, 24 provides patients with an instant boost. Furthermore, the fact that the two moieties are inseparable, implies that compliance with anti-inflammatory therapy might be enhanced as the LABA (which the patient perceives as beneficial shortly after dosing) cannot be used at the expense of inhaled corticosteroid.
Possible drawbacks
Despite the advantages of a single inhaler, on a practical level altering the inhaled corticosteroid dose, without altering the LABA dose, becomes less straightforward. This has the potential consequence that patients may remain on unnecessary or insufficient doses of anti-inflammatory treatment for a prolonged period of time. Indeed, due to the variable nature of asthma, patients are advised to adjust their inhaled corticosteroid dose according to symptoms and personal best peak expiratory flow (PEF). 6 An evidenced-based review by Gibson and Powell highlighted the benefit of written action plans-involving at least doubling the inhaled corticosteroid dose-when incorporated into the routine care of asthmatic patients. 34 During periods of deteriorating asthma control, patients using a Seretide Accuhaler would therefore require a separate inhaler in order to titrate upwards the dose of fluticasone. Similarly, when asthma is well controlled and ''step-down'' considered appropriate, patients would have to consult their primary care physician to be provided with a further inhaler containing less corticosteroid. In order to overcome this difficulty, Symbicort-largely due to the less steep dose-response curve of eformoterol com-pared to salmeterol 24 -can be used in a more flexible manner. This allows different corticosteroid doses to be delivered to the lung along with a variable dose of eformoterol. Indeed, in a study by Aalbers et al., 35 an adjustable maintenance dose of twice daily budesonide 160 mg plus eformoterol (in a single inhaler) was shown to provide effective asthma control when individuals were instructed to titrate treatment according to symptoms. Moreover, when compared to a fixed fluticasone plus salmeterol dosing regime, there were 40% (P ¼ 0:018) fewer exacerbations.
Considerable concern has been focused on the use of LABAs and the masking of underlying airway inflammation. Theoretically, patients may use such drugs for relatively instant bronchodilation and adhere less stringently to inhaled corticosteroid therapy (when used as separate inhalers). This in turn could result in persisting chronic mucosal inflammation of which the patient is unaware, in turn paving the way towards an exacerbation. Indeed, in a study by McIvor et al., the use of salmeterol controlled symptoms and maintained bronchodilation but resulted in an increase of sputum eosinophils when inhaled corticosteroids were tapered in 13 asthmatics. 36 This small study of patients using daily doses of inhaled corticosteroid X1500 mg may not be applicable to ''real-life'', as doses were reduced until either criteria for an exacerbation was reached or until no corticosteroids were being used at all. In another study, after a run-in using budesonide 1600 mg/day, 60 moderately severe asthmatics were randomised to receive budesonide 800 mg/day (mean FEV 1 82% predicted) or budesonide 200 mg/day plus eformoterol (mean FEV 1 84% predicted). 37 After 1 year of randomised treatments, there were no differences in either surrogate markers of inflammation and perhaps surprisingly of lung function. Thus, this Effects of long acting b 2 -agonists as addon therapy to inhaled corticosteroids
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Mild asthmatics
Inhaled corticosteroids are advocated to be used as 1st line controller therapy in persistent asthmatics over and above intermittent short acting b 2agonists. 6 Moreover, regular use of short acting b 2 -agonists demonstrates no benefit in long term asthma control. [38] [39] [40] However, the question of whether mild persistent asthmatics now should be treated with inhaled corticosteroids in combination with LABAs arises, mainly in recognition of their demonstrated beneficial effects in patients with more severe disease over anti-inflammatory therapy as monotherapy. 41 A study by O'Byrne et al. evaluated the effects of placebo, budesonide 200 mg/day as monotherapy or combined with eformoterol in 698 corticosteroid naïve asthmatics. 42 Symptomatic patients had a mean FEV 1 of approximately 90% predicted in all three randomised groups. After 1 year of treatment, those receiving budesonide alone had a 60% and 48% reduction in risk of first severe asthma exacerbation and rate of poorly controlled asthma days, respectively, compared to placebo. Budesonide treated patients also benefited from a reduction in symptoms and increase in FEV 1 . Compared to inhaled corticosteroid alone, concomitant treatment with eformoterol conferred no other improvement other than significant (although unlikely to be clinically so) small improvements in FEV 1 (1.8% predicted, P ¼ 0:023) and PEF (15 L/min, P ¼ 0:0001). In the same study, 1272 mild asthmatics using p400 mg/day of inhaled corticosteroid were randomised to receive budesonide 200 mg/ day, budesonide 200 mg/day plus eformoterol, budesonide 400 mg/day or budesonide 400 mg/day plus eformoterol. In these symptomatic patients (mean FEV 1 of approximately 86% predicted), the addition of eformoterol to either budesonide dose reduced the risk of first asthma exacerbation by 43% and poorly controlled asthma days by 30%, respectively. Adding eformoterol to budesonide 200 mg/day was more effective than doubling the dose of the latter in terms of asthma control.
Another study evaluated the effects of add-on eformoterol in mild patients receiving o400 mg/ day of beclomethasone or equivalent. 43 In this multi-centre study, 663 symptomatic mild asthmatics (mean PEF 74% predicted) were randomised to receive budesonide 800 mg/day plus either eformoterol or placebo. After 4 weeks, patients whose asthma was well controlled (n ¼ 505) were randomised again to receive budesonide 400 mg/day plus eformoterol or placebo for further 6 months. It was discovered that the addition of eformoterol to either dose of budesonide resulted in more effective control of asthma. However, it is relevant to point out that comparison of additional effects of the LABA were only being made to placebo (and not for example a higher inhaled corticosteroid dose or alternative 2nd line controller). In another study, 44 the combination of fluticasone 200 mg/day plus salmeterol was compared to fluticasone 200 mg/ day alone in patients (mean PEF of around 80% predicted) only using short acting b 2 -agonists for as required use. Compared to fluticasone alone, combination therapy conferred significant improvements in terms of daytime symptom scores and diurnal PEF over a 24 week period. No differences were observed in nighttime symptoms or frequency of short acting b 2 -agonist use. Moreover, it is relevant to point out that no assessment of underlying inflammation or AHR was made, while a third randomised limb evaluating the comparative effects of double the dose of fluticasone (400 mg/day) would have been of potential interest.
In mild asthmatics there is generally a paucity of data concerning the use of LABAs in conjunction with inhaled corticosteroids with the consequence that definite conclusions are difficult to make. However, it is reasonable to believe that such patients with essentially normal lung function, should continue to be treated with an inhaled corticosteroid alone; those with persistent symptoms (and especially with impaired lung function) could proceed to have a therapeutic trial of LABA. However, further trials are required to compare the effects of initiating asthma treatment with an inhaled corticosteroid alone versus add-on LABA especially in mild asthmatics with both completely normal and also mildly impaired lung calibre. Ideally these should evaluate effects upon a variety of endpoints such as symptoms, lung function, biomarkers of airway inflammation, AHR and airway remodelling.
Moderate to severe asthmatics
An important early study into the use of LABAs evaluated 429 asthmatics uncontrolled on beclomethasone 400 mg/day. 45 Individuals were rando-mised to receive more than double their preexisting inhaled corticosteroid dose (1000 mg/day) or add-on treatment with salmeterol for 6 months. Patients using concomitant LABA demonstrated greater lung function and fewer symptoms than those using inhaled corticosteroid alone, although no difference in exacerbation rates were observed between the two groups. It is also important to note that effects upon surrogate biomarkers of inflammation or AHR were not measured. In another study, Woolcock et al. randomised 738 asthmatics not controlled on beclomethasone 1000 mg/day to receive either double their inhaled corticosteroid dose, or addition of twice daily salmeterol 50 mg or 100 mg. 46 No differences were observed upon exacerbation rates or AHR in all three groups, but patients who were treated with either dose of LABA benefited from fewer symptoms and a greater PEF. In the multicentre study by Pauwels et al., 47 optimising the inhaled corticosteroid dose to 800 mg/day of budesonide and then adding eformoterol, resulted in a significantly reduced number of severe exacerbations compared to adding eformoterol to 200 mg/day of budesonide (a 49% versus 26% reduction, respectively). In other words, budesonide reduced exacerbations by its anti-inflammatory effect, while eformoterol produced a further reduction by stabilising airway smooth muscle in patients using the higher budesonide dose. In the same study, there was also a disconnect between lung function and exacerbations; in other words, despite a reduction in exacerbations, FEV 1 and PEF were unchanged when comparing budesonide 200 mg/day versus budesonide 800 mg/day. This indicates that when optimising the dose of inhaled corticosteroid, lung function is relatively distant from the underlying inflammatory process and despite no change in value, further beneficial clinical effects may actually be apparent. Thus, while endpoints such as lung function are of undoubted value, clinicians must not lose sight of the basic pathophysiological hallmarks of the asthma syndrome (i.e. AHR and inflammation) along with the impact of asthma pharmacotherapy upon exacerbations.
In a meta-analysis (n ¼ 9 trials, 3685 patients), Shrewsbury et al. evaluated the effects of increasing the dose of inhaled corticosteroid versus the addition of salmeterol. 41 Add on therapy with LABA tended to be superior on most lung function endpoints and symptoms. However, despite no trial included in the meta-analysis conferring a significant reduction in exacerbations, there was a small but significant reduction (2.4%) in severe exacerbations on pooling of the results.
Interactions between inhaled corticosteroids and long acting b 2 -agonists
Despite knowledge that co-administered inhaled corticosteroids plus LABAs are superior to doubling the dose of the former in terms of asthma control, it has previously been considered that both agents work independently of one another. In other words, inhaled corticosteroids exert potent anti-inflammatory effects while the LABA moiety relaxes airway smooth muscle. However, recent studies have demonstrated that beneficial synergism may occur on a molecular and histological basis.
Roth et al. evaluated the effects of budesonide and eformoterol (alone and in combination) upon transcription factors and cell proliferation. 48 The combination of inhaled corticosteroid plus LABA provided a synergistic effect upon transcription factors and an inhibitory effect on smooth muscle cell proliferation. In another study, salmeterol enhanced the activation of the glucocorticoid receptor in primary human lung fibroblasts and vascular smooth muscle cells. 49 In a placebo controlled study involving 45 symptomatic asthmatics receiving inhaled corticosteroids, the effects of supplemental salmeterol was examined in by way of changes in bronchial biopsy material. 50 Patients treated with a LABA showed a significant reduction in blood vessel density in lamina propria which the authors suggested could have been as a direct consequence of modifications of angiogenic growth factors.
Conversely, corticosteroids have been shown to influence the effects of b 2 adrenergic receptors. For example, they can regulate b 2 adrenergic receptor function by increasing its expression through gene transcription. 51 Moreover, they also demonstrate an inhibitory effects upon G-protein coupling and b 2 adrenergic receptor downregulation, and in turn desensitisation. 52 In light of these observations, it can be seen that there is interplay between both moieties on a molecular level, however there is far less convincing evidence that the observed synergy between inhaled corticosteroids and LABA actually translates into ''real-life'' benefit. For example, in a randomised controlled crossover study in mild-to-moderate asthmatics (mean FEV 1 80% predicted), fluticasone 500 mg/day plus salmeterol was compared to double the dose of fluticasone alone. The latter treatment conferred significant superiority in terms of surrogate inflammatory markers comprising of adenosine monophosphate threshold concentration and exhaled nitric oxide (Fig. 1) . In another study, fluticasone 500 mg/day plus salmeterol in combination was no different from fluticasone 500 mg/day alone on exhaled nitric oxide, adenosine monophosphate threshold concentration and blood eosinophils (Fig. 2) .
Thus, while data of Roth 48 and Eickelberg 49 show interesting in vitro observations to suggest a positive and beneficial interaction between the two moieties, this has not been substantiated by in vivo work. Nonetheless, inhaled corticosteroids and LABAs do provide complementary effects on inflammation and smooth muscle dysfunction, respectively, which frequently results in improved asthma control when taken together.
Comparison of add on long acting b 2agonists versus other 2nd line agents
Prior to escalation of treatment, symptomatic asthmatics should have inhaler technique checked and compliance assessed, along with an effort to look for co-existent conditions such as allergic rhinitis or gastro-oesophageal reflux disease which may be contributing to symptoms. After doing so, current guidelines suggest that in asthmatics not controlled on a low-to-medium dose of inhaled corticosteroid (400-800 mg/day of beclomethasone or equivalent) a therapeutic trial of add-on LABA should be considered (step 3). 6 Only in patients who subsequently remain symptomatic (step 4) or derive no benefit from the addition of a LABA, the addition of a leukotriene receptor antagonist (LTRA) or theophylline should be considered. Table 2 shows the relative properties of possible 2nd line controller therapies.
Leukotriene receptor antagonists
Despite transforming asthma management, inhaled corticosteroids do not suppress all aspects of inflammation. For instance, it has become apparent that eosinophilic inflammation can persist despite high doses of inhaled corticosteroids, 53, 54 while oral corticosteroids can cause an increase in the number of neutrophils. 55 It is also of potential therapeutic importance that inhaled corticosteroids have a limited impact on the synthesis or release of cysteinyl leukotrienes. 56, 57 The cysteinyl leukotrienes (C 4 , D 4 and E 4 ) are lipid mediators which are implicated in producing an array of effects such as bronchoconstriction, increased vascular permeability, mucous secretion, inflammatory cell recruitment and airway smooth muscle proliferation. Antagonism of the effects of cysteinyl leukotrienes can be achieved by drugs preventing their synthesis using a 5-lipoxygenase inhibitor, or blocking specific leukotriene receptors using a LTRA. Currently two LTRAs are licensed for clinical use in Europe, namely montelukast and zafirlukast. These drugs demonstrate bronchodilator and anti-inflammatory properties and can attenuate AHR to a variety of bronchoconstrictor stimuli. 58 A further therapeutic benefit is that LTRAs exert their effects following single doses and are orally active. This latter property may enhance compliance especially in children, adolescents and the elderly in whom technical difficulties associated with and dislike of inhaled medication may occur. Furthermore, unlike LABAs, tolerance to their bronchoprotective effects has not been demonstrated.
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A number of studies have performed head-tohead comparisons of add-on therapy with a LTRA compared to LABA in uncontrolled asthmatics using inhaled corticosteroids alone. In a double blind, double dummy, parallel group, multicentre trial over 12 weeks, it was demonstrated that the addition of salmeterol was superior to that of add-on montelukast 10 mg/day in uncontrolled asthmatics using inhaled corticosteroids. 59 This was in terms of measures of lung calibre (the primary endpoint), salbutamol use and symptom scores. Similarly, in a multi-centre trial, Nelson et al. demonstrated that adding salmeterol to fluti-casone was superior to concomitant treatment with zafirlukast 20 mg twice daily. 60 Indeed, compared with oral zafirlukast, treatment with salmeterol conferred significantly greater improvements in pulmonary function, relief of both daytime and nighttime asthma symptoms and Asthma Quality of Life Questionnaire. It is pertinent to consider that in these studies, the primary endpoint was lung function which in turn can be considered as being ''smooth muscle dependant'', or in other words, one in which the effects of a LABA would likely be greater than those of a LTRA.
Two more recent studies have examined the effects of add-on LABA or LTRA in terms of exacerbation frequency. For example, 1490 chronic asthmatics uncontrolled on inhaled fluticasone 200 mg/day, were randomised to receive add-on montelukast 10 mg/day or salmeterol. 61 After a year of treatment, 20.1% of patients in the montelukast group compared with 19.1% in the salmeterol group experienced an exacerbation of asthma, with no significant difference between randomised treatments. However, salmeterol treated patients had a greater FEV 1 and morning PEF (Pp0:001), while the combination of fluticasone plus montelukast conferred a greater reduction (P ¼ 0:011) upon blood eosinophils than add-on salmeterol. Moreover, similar to previous in vivo data, 62, 63 no potentiation of the anti-inflammatory effects of inhaled corticosteroids by the LABA moiety was observed in this study. In another multi-centre study using 1473 symptomatic asthmatics, the effects of add-on montelukast 10 mg/ day or salmeterol to fluticasone 220 mg/day were evaluated. 64 After 48 weeks, no significant difference in exacerbation frequency was observed between treatments. However, salmeterol improved lung function and symptom scores to a greater extent than montelukast, although the latter provided significantly greater effects upon blood eosinophils.
It can therefore be seen that in trials evaluating the addition of a LABA or LTRA, the choice of primary endpoint is crucial in determining which treatment confers superiority. Moreover, many trials in asthmatics have a prerequisite to entry of reversibility of 15% to short acting bronchodilator, irrespective of extent of underlying inflammation or AHR. While this is one of the classical feature in the diagnosis of asthma, it may not be representative of the asthmatic population at large and is not crucial in making the diagnosis. 6 Indeed, many symptomatic asthmatics demonstrate preserved lung function which in turn suggests that underlying inflammation and AHR are the driving forces behind symptoms and exacerbations. 65, 66 It remains to been whether in future updated guidelines the addition of a LTRA to a low-to-moderate inhaled corticosteroid dose sits more comfortably beside add-on LABA.
Theophyllines
Theophyllines are phosphodiesterase inhibitors which have some additional effect in asthmatics when added to inhaled corticosteroids. They are weak bronchodilators and possess some anti-inflammatory action. Their use is frequently limited due to concerns of cardiac arrhythmias, gastrointestinal upsets and the need for monitoring plasma levels due to a narrow therapeutic index. Moreover, there is considerable variation in the half-life of theophyllines and care requires to be taken in for example, smokers, patients with liver disease or heart failure and those taking certain drugs. A meta-analysis (n ¼ 9 trials, 1330 patients) directly compared the effects of theophylline versus salmeterol in asthmatics and concluded that the use of a LABA was significantly superior in terms of lung function and symptoms along with a more favourable adverse effect profile. 67 
Conclusions
The use of an inhaled corticosteroid plus LABA in a single inhaler is likely to continue to increase in popularity in view of its convenience, efficacy and beneficial effects upon exacerbation reduction. Moreover, this provides patients with a convenient and effective treatment which deals concomitantly with suppression of underlying inflammation and relaxation of bronchial smooth muscle. Patients are also likely to prefer this option, as compared to a higher inhaled corticosteroid dose, in view of better symptom control plus reducing the risk of local and systemic adverse sequelae.
Initial concerns regarding the problem of masking underlying inflammation with the LABA moiety has not been substantiated to any great degree. However, there are few data comparing their effects versus higher doses of inhaled corticosteroids in terms of airway remodelling. Indeed, in a study by Ward et al., 68 significant reductions in basement membrane thickness did not occur until after 3 months of high dose inhaled corticosteroid treatment (1500 mg/day of fluticasone). Moreover, Reddel et al. 69 demonstrated that patients starting with 3200 mg/day of budesonide had greater normalisation in AHR and fewer exacerbations than even 1600 mg/day of budesonide. It is therefore important to ensure that untoward long-term sequelae do not occur at the expense of short-term superior bronchodilation with the use of LABAs. Further prospective studies incorporating surrogate inflammatory biomarkers and parameters reflecting airway remodelling are therefore required to fully evaluate the effects of combination inhalers versus, for example, double the inhaled corticosteroid dose.
It is also important for prescribing clinicians to be aware of the relative lack of data advocating their use in patients with very mild-although persistent-disease, especially when lung function (FEV 1 ) is not compromised. In other words, in many such patients airway calibre cannot be further improved and it is in fact the underlying airway inflammation and AHR which requires treatment with antiinflammatory therapy to alleviate symptoms. Moreover, perhaps in these patients who have persistent symptoms despite the use of a low-to-moderate inhaled corticosteroid dose, the addition of a LTRA might be the more sensible pharmacological intervention in view of beneficial effects upon attenuating AHR and inflammation.
In more severe patients, the study by Pauwels succinctly demonstrated the benefits of optimising the inhaled corticosteroid dose to 800 mg/day of budesonide, prior to introduction of a LABA. 47 It is important to be aware however that there is a degree of interindividual variability in terms of response to inhaled corticosteroids. In other words, not all asthmatic patients require the same inhaled corticosteroid dose in which to suppress inflammation to a satisfactory degree and therefore at which point further 2nd line therapy is required for persistent symptoms varies. Indeed, the problem with conventional measures of asthma control remains the fact that they are distant from the pathophysiological hallmarks and merely reflect the clinical consequences of a cascade of complex cellular events. Moreover, ''mean patients'' are often created from the findings of multi-centre randomised controlled trials and meta-analysis, the results from which have been derived from many thousands of individuals across a range of socioeconomic backgrounds, asthma phenotype, age and racial background.
To overcome these difficulties in an ideal world, clinicians would have access to a reliable surrogate inflammatory biomarker (Table 3 ). This in turn would provide information as to when exactly corticosteroid responsive inflammation was adequately suppressed and when additional 2nd line controller therapy such as a LABA to maximally dilate the airway should be instituted. For example, in a study by Green et al., an asthma management strategy targeted against a surrogate inflammatory marker (sputum eosinophils) led to significantly fewer severe asthma exacerbations than using standard guidelines alone. 70 Moreover, the effects on eosinophils and other inflammatory markers were dissociated from lung function and symptoms. However, the practicality of performing sputum induction in everyday clinical practice, especially in terms of obtaining instant feedback of the result for the patient in the clinic is questionable. Perhaps in the future, clinicians will have ready access to a convenient tool in which to monitor the extent of underlying airway inflammation, help tailor pharmacotherapy to individual patients and in turn reduce the burden of asthma in both primary and secondary care. Table 3 Characteristic features of the ideal surrogate inflammatory marker in asthma.
Raised only in asthma
Raised only when endobronchial inflammation is present Simple and cheap to measure Easy to measure in primary and secondary care settings Patient acceptability Linear reduction on institution of anti-inflammatory therapy with clear cut dose-response effect Demonstrated to provide superior clinical control when used along with conventional measures than the latter alone
